Kakao Healthcare

Kakao Healthcare has rapidly established itself as South Korea’s leading provider of AI-driven digital healthcare solutions since its spin-off from Kakao Corporation in late 2022. The company focuses on hyper-personalized virtual care—especially diabetes management—by integrating real-time CGM sensor data with mobile applications powered by artificial intelligence. Its flagship products include Project Gamma and the PASTA app, both designed to improve outcomes for people with diabetes through advanced analytics and seamless device integration. Beyond patient-facing apps, Kakao Healthcare operates a robust hospital-focused data platform that standardizes and anonymizes large-scale clinical datasets across major Korean hospitals using federated learning technology. This enables secure multi-center research collaboration without moving sensitive personal information offsite—a key advantage cited by pharmaceutical partners seeking to accelerate new drug development or optimize real-world evidence studies. The company has signed high-profile partnerships with Novo Nordisk to enhance its diabetes offerings globally, Dexcom to integrate next-generation CGM devices, Google Cloud to power its federated learning infrastructure, Signature HealthCare for mental health remote monitoring pilots in the US, BIOCORP for smart insulin pen sensors, C&R RESEARCH as an industry CRO partner, Huons regarding Dexcom G7 distribution, among others. Kakao Healthcare’s business model centers around providing B2B/B2G SaaS-style access to its medical big-data platforms while also offering consumer-facing mobile applications targeting chronic disease self-management. It currently collaborates with at least seventeen major general hospitals domestically—with ten already fully standardized—and has begun international expansion into Japan via local subsidiaries. The company does not develop drugs or biologics but instead provides enabling technologies/platforms that support life science R&D, precision medicine initiatives, decentralized trials, remote patient monitoring programs, and population-level analytics.